With Stringent Oversight, Heritable Germline Editing Clinical Trials Could One Day Be Permitted for Serious Conditions; Non-Heritable Clinical Trials Should Be Limited to Treating or Preventing Disease or Disability at This Time

Clinical trials for genome editing of the human germline – adding, removing, or replacing DNA base pairs in gametes or early embryos – could be permitted in the future, but only for serious conditions under stringent oversight, says a new report from the National...

NASEM Publications Round-Up: January 2017

Browse all publications released in January 2017 below. To receive updates from the NAM, please subscribe to our mailing list. Reports document the evidence-based consensus of an authoring committee of experts. Proceedings chronicle the presentations and discussions...

Join Our Community

Sign up for NAM email updates